Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma

Abstract

Background In the present study, we have tried to understand how the level of risk and survival probability changes over time for patients with classical Hodgkin’s lymphoma by employing conditional survival and annual hazard as dynamic estimates of prognosis and survival. Methods This retrospective study reviewed the clinical data of patients with newly diagnosed classical Hodgkin’s lymphoma admitted to Peking University Cancer Hospital between January 1, 2008, and December 31, 2017. Conditional survival and annual hazard rate were defined as the survival probability and yearly event rate, respectively, assuming that patients have survived for a defined time. Results A total of 384 patients were included (median age, 32 years; range, 6–77 years), of which 218 (56.8%) patients had early-stage disease. The median follow-up time was 41.3 months. The 5-year conditional overall survival (COS) rates remained favorable and showed an increase from 89% at treatment to 94% at year 5, while the 5-year conditional failure-free survival (CFFS) rate increased from 70% at treatment to 96% at year 5. The annual hazard of failure decreased from over 15% at diagnosis to less than 5% after 3 years. Early-stage patients had constantly lower annual estimates for hazard of death (range, 0–3.0%) and failure (range, 0–14.3%). However, the hazard of failure in advanced-stage patients decreased from 24.2% at diagnosis to below 8% after 3 years, whereas the hazard of death was always at relatively low levels. Patients with a high IPS risk score (≥3) had significantly lower COS and CFFS during the first 4 years. Patients who received the BEACOPP regimen had better 5-year COS and 5-year CFFS than those who received the ABVD regimen. Conclusion The survival probability increased and hazard of failure decreased over time.

A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic colorectal cancer

“…The development of a novel conditional survival nomogram for monitoring real-time prognosis in CRC patients marks a significant milestone in the field, as corroborated by previous studies [ 12 , 19 , 20 ]. This personalized tool integrates time-varying covariates and patient-specific characteristics to furnish individualized survival estimates at specific time intervals, thereby bolstering the foundation for tailored treatment decision-making [ 21 , 22 ]. By offering real-time prognostic information, the nomogram serves as a valuable resource in patient counseling and shared decision-making processes, facilitating the dissemination of tailored survival estimates at distinct time points [ 23 ].…”

Conditional survival analysis and real-time prognosis prediction for cervical cancer patients below the age of 65 years

“…Conditional survival (CS) is a promising survival metric that calculates survival over time and is defined as the probability that a patient who has survived for x years after diagnosis of cervical cancer will survive for another y years ( 4 , 5 ). As we know, this metric has been applied in pancreatic adenocarcinoma ( 6 , 7 ), gastric cancer ( 8 ), esophageal cancer ( 9 ), liver cancer ( 10 ), lung cancer ( 11 ), nasopharyngeal carcinoma ( 12 ), colorectal cancer ( 13 ), Hodgkin lymphoma ( 14 ), and melanoma ( 15 ), and dynamic improvements in prognosis over time have been observed. This favorable survival characteristics can provide significant support for cancer management, such as psychological support for patients, adjustment of follow-up frequency, optimal risk stratification, and guidance for adjuvant treatment decisions, which have important clinical value for patients and clinicians.…”

Conditional survival and annual hazard of death in elderly patients with esophageal cancer receiving definitive chemoradiotherapy

“…[ 8 ] Uncertainty about prognosis can cause psychological stress and even affect post-treatment prognosis. [ 9,10 ] Conditional survival is an important concept in the eld of oncology [ [11][12][13][14][15]; it refers to the dynamic change in the likelihood of survival over time after diagnosis or treatment. [ 16,17 ] This dynamic measurement can provide updated survival estimates at speci c time points after treatment and help guide long-term follow-up strategies.…”